The STR platform has novel properties designed to ellicit a native immune response, which may increase the response rate of current immunotherapies in solid tumors. By binding bacterial determinants to the tumor surface, the technology effectively converts a weak immune response to a powerful, but specific, antibacterial immune reaction. STR technology carries the potential to augment the effectiveness of checkpoint inhibitors and other anticancer approaches.
NeoTX’s first clinical STR candidate, naptumomab estafenatox (NAP), is currently being evaluated for advanced solid tumors. Additional drug candidates developed with the STR platform have the potential for treating hematologic cancers and additional solid tumor indications such as glioblastoma. While the STR platform is currently in clinical trials in combination with checkpoint inhibitors, STR may enhance other therapeutic modalities.
Additionally, NeoTX is actively exploring in-licensing deals and partnerships that give the company access to new early-stage drugs that would be complementary to the STR platform.
Naptumomab estafenatox (NAP), NeoTX’s lead candidate, and the first STR platform drug to enter the clinic, is currently in a Phase 1b clinical trial for advanced and metastatic solid tumor indications. NAP was licensed from Active Biotech (NASDAQ STOCKHOLM: ACTI) in 2016 and has potential for investigation as monotherapy and in combination with other modalities, including chemotherapy, CAR-T cell therapy and checkpoint inhibitors.
NAP is directed against tumors expressing 5T4 antigen, which is present on many types of cancers, including the most frequent solid tumors.
Previous clinical trials have found NAP to be well-tolerated and demonstrated preliminary signals of efficacy. A Phase 1b clinical trial of NAP in combination with a checkpoint inhibitor is ongoing.
• Breast cancer
• Cervical cancer
• Colorectal cancer
• Gastric cancer
• Pancreatic cancer
• Prostate cancer
• Renal cell cancer